ABSTRACT
CONTEXT: Type 1A diabetes is characterized by a long prodromal phase during which autoantibodies to islet antigens are present. Nevertheless, we lack data on the pancreatic pathology of subjects who are positive for islet autoantibodies (to islet autoantigens GAD65, insulin, and ICA512). OBJECTIVE: In this manuscript, we describe a novel strategy in obtaining pancreata and pancreatic lymph nodes from islet autoantibody-positive organ donors that involves careful coordination among the laboratory and the organ donor provider organization. DESIGN: We developed a rapid screening protocol for islet autoantibodies measurement of organ donors to allow identification of positive subjects before organ harvesting. In this way we were able to obtain pancreata and pancreatic lymph nodes from subjects with and without islet autoimmunity. SETTING: The organ donors used in this study were obtained from the general community. SUBJECTS: The population studied consisted of 112 organ donors (age range 1 month to 86 yr, mean age 39 yr). MAIN OUTCOME MEASURE: The main outcome measure of this study consisted of evaluating the pancreatic histology and identify T cells autoreactive for islet antigens in the pancreatic lymph nodes. RESULTS: To date we have identified three positive subjects and obtained the pancreas for histological evaluation from one of the autoantibody-positive donors who expressed ICA512 autoantibodies. Although this subject did not exhibit insulitis, lymphocytes derived from pancreatic lymph nodes reacted to the islet antigen phogrin. CONCLUSION: In summary, these results indicate that it is possible to screen organ donors in real time for antiislet antibodies, characterize pancreatic histology, and obtain viable T cells for immunological studies.
Subject(s)
Autoantibodies/analysis , Islets of Langerhans/immunology , Tissue Donors , Adolescent , Adult , Aged , Chromogranins/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Fibrosis , Glucagon/analysis , Glucagon/metabolism , Humans , Immunohistochemistry , Insulin/analysis , Insulin/metabolism , Islets of Langerhans/pathology , Keratins/metabolism , Leukocyte Common Antigens/analysis , Lymph Nodes/cytology , Lymph Nodes/immunology , Lymph Nodes/pathology , Male , Middle Aged , Pancreas/metabolism , T-Lymphocytes/immunologyABSTRACT
BACKGROUND: Recent studies suggest that the appearance of anti-HLA antibodies in the early posttransplant period is associated with an increased incidence of acute and chronic rejection months later. However, very little is known about the prevalence of anti-HLA antibodies at the time that the rejection episodes are diagnosed. The purpose of this study was to analyze retrospectively 420 sera from 263 renal allograft recipients who were readmitted to the hospital for any reason between 1989 and 1998 in order to determine if a correlation existed between the presence of donor-specific anti-HLA antibodies and graft rejection. METHODS: Sera were assayed for IgG HLA class I and II antibodies by ELISA. The ELISA results were analyzed using contingency tables with Fisher's exact test and compared with mismatched antigens in the donor. RESULTS: Antibodies to donor HLA class I molecules in the posttransplant sera were extremely rare, occurring in only 6 of the 420 sera (1.4%) analyzed. Antibodies to donor class II antigens were slightly more common, occurring in 25 of the 420 sera (6%). In 21 of these 25 cases (84%), the presence of donor-specific HLA class II antibodies was associated with episodes of either acute (n=14) or chronic rejection (n=7). Five patients had antibodies to both class I and class II donor antigens, and all five of them lost their grafts to rejection. CONCLUSION: Although the presence of donor-specific HLA antibodies presented a significant risk for acute or chronic rejection, 77% of all acute and chronic rejections occurred in patients without detectable HLA antibodies.
Subject(s)
Histocompatibility Antigens Class I/immunology , Kidney Transplantation/immunology , Antibodies/blood , Antibody Specificity , Graft Rejection/epidemiology , Graft Rejection/immunology , Histocompatibility Antigens Class II/immunology , Humans , PrevalenceSubject(s)
Antigens, Bacterial/analysis , Immunoassay/methods , Streptococcal Infections/diagnosis , Streptococcus pyogenes/isolation & purification , Adolescent , Adult , Bacteriological Techniques , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Pharyngitis/diagnosis , Pharynx/microbiology , Reagent Kits, Diagnostic , Sensitivity and Specificity , Streptococcus pyogenes/immunologyABSTRACT
We produced a panel of monoclonal autoantibodies from the spleen cells of prediabetic nonobese diabetic mice. The antibodies were selected on the basis of their ability to bind to the surface of nondiabetic mouse islet cells, and from greater than 4000 hybridomas screened, 35 islet-reactive antibodies were isolated. Most of these reagents also bind to nondiabetic rat and human islet cells and beta-cell tumor lines. A few of the antibodies were found to be reactive with insulin. When tested for cross-reactivity with other cell types, most of the antibodies were found to be islet specific.